ECSP034891A - Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa - Google Patents
Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampaInfo
- Publication number
- ECSP034891A ECSP034891A EC2003004891A ECSP034891A ECSP034891A EC SP034891 A ECSP034891 A EC SP034891A EC 2003004891 A EC2003004891 A EC 2003004891A EC SP034891 A ECSP034891 A EC SP034891A EC SP034891 A ECSP034891 A EC SP034891A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- derivatives
- alkyloxy
- independently
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de benzoxazepina que tiene la fórmula general I, en la cual X representa CO o SO2; R1, R2, R3 y R4 son independientemente seleccionados desde H, (C 1-4) alquilo, (C 1-4) alquiloxi, (C 1-4)alquiloxi(C 1-4)alquilo, CF3, halógeno, nitro, ciano, NR8R9, NR8COR10, y CONR8R9; R5, R6 y R7 son independientemente H o (C 1-4)alquilo; R8 y R9 son independientemente H o (C 1-4)alquilo; o R8 y R9 forman junto con el átomo de nitrógeno al cual están unidos al anillo heterocíclico saturado membrado 5- o 6-, conteniendo opcionalmente un hetero átomo adicional seleccionado desde O, S, o NR11; R10 es (C 1-4)alquilo; R11 es (C 1-4)alquilo; A representa el residuo de un anillo heterocíclico saturado membrado 4-7, opcionalmente conteniendo un átomo de oxígeno, el anillo siendo opcionalmente sustituido con sustituyentes 1-3 seleccionados desde (C 1-4)alquilo, (C 1-4)alquiloxi, hidroxi, halógeno u oxo; o una sal farmacéuticamente aceptable del mismo. LA invención también e refiere a composiciones farmacéuticas que comprenden dichos derivados, y el uso de estos derivados de benzoxazepina en el tratamiento de enfermedades neurológicas y desórdenes psiquiátricos los cuales responden al aumento de las respuestas sinápticas intermediadas por los receptores AMPA en el sistema nervioso central.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202215 | 2001-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034891A true ECSP034891A (es) | 2004-01-28 |
Family
ID=8180450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004891A ECSP034891A (es) | 2001-06-11 | 2003-12-11 | Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7307073B2 (es) |
| EP (1) | EP1399450B1 (es) |
| JP (1) | JP4435561B2 (es) |
| KR (1) | KR100863255B1 (es) |
| CN (1) | CN1257908C (es) |
| AR (1) | AR036092A1 (es) |
| AT (1) | ATE389659T1 (es) |
| AU (1) | AU2002314144B2 (es) |
| BR (1) | BR0210222A (es) |
| CA (1) | CA2450274C (es) |
| CO (1) | CO5550447A2 (es) |
| CZ (1) | CZ300052B6 (es) |
| DE (1) | DE60225689T2 (es) |
| EC (1) | ECSP034891A (es) |
| ES (1) | ES2301651T3 (es) |
| HR (1) | HRP20031007A2 (es) |
| HU (1) | HUP0400154A3 (es) |
| IL (2) | IL158905A0 (es) |
| IS (1) | IS2526B (es) |
| MX (1) | MXPA03011563A (es) |
| NO (1) | NO328705B1 (es) |
| NZ (1) | NZ529670A (es) |
| PE (1) | PE20030097A1 (es) |
| PL (1) | PL366721A1 (es) |
| RU (1) | RU2279434C2 (es) |
| SK (1) | SK287150B6 (es) |
| TW (1) | TWI232863B (es) |
| WO (1) | WO2002100865A1 (es) |
| ZA (1) | ZA200309382B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255413C (zh) | 2001-06-14 | 2006-05-10 | 阿克佐诺贝尔公司 | 作为ampa受体正性调节剂的(吡啶并/噻吩并)－[f]－氧杂吖庚因－5－酮衍生物 |
| US20110218190A1 (en) * | 2008-11-10 | 2011-09-08 | The Regents Of The University Of California | Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction |
| TWI423980B (zh) * | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| FR2964969B1 (fr) * | 2010-09-16 | 2012-08-24 | Servier Lab | Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3311842A1 (en) | 2013-06-13 | 2018-04-25 | VeroScience LLC | Compositions and methods for treating metabolic disorders |
| EP3436021B1 (en) | 2016-03-29 | 2026-07-29 | RespireRx Pharmaceuticals, Inc. | Compositions comprising low impact ampakines for treating attention deficit disorders |
| JP7113009B2 (ja) | 2016-11-07 | 2022-08-04 | アービュタス バイオファーマ コーポレイション | 置換ピリジノン含有三環式化合物およびそれを使用する方法 |
| TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
| TW202010499A (zh) | 2018-04-12 | 2020-03-16 | 加拿大商愛彼特生物製藥公司 | 經取代的吡啶酮之三環化合物的製備方法 |
| CA3120532C (en) | 2018-11-22 | 2023-09-26 | Fujian Cosunter Pharmaceutical Co., Ltd. | Crystal form of hepatitis b surface antigen inhibitor |
| US20230218632A1 (en) * | 2020-03-20 | 2023-07-13 | Amathus Therapeutics, Inc. | Cyclic sulfonamide derivatives as trap1 modulators and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1238719A (es) | 1968-11-01 | 1971-07-07 | ||
| DE69331761T2 (de) | 1992-07-24 | 2002-09-12 | The Regents Of The University Of California, Oakland | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
| CN1168140A (zh) | 1995-01-06 | 1997-12-17 | 弗·哈夫曼-拉罗切有限公司 | 羟甲基咪唑并二氮杂䓬及其酯 |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| ES2245015T3 (es) | 1997-06-09 | 2005-12-16 | Pfizer Products Inc. | Quinazolin-4-onas como antagonistas de ampa. |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
-
2002
- 2002-05-31 TW TW091111746A patent/TWI232863B/zh not_active IP Right Cessation
- 2002-06-05 JP JP2003503632A patent/JP4435561B2/ja not_active Expired - Lifetime
- 2002-06-05 IL IL15890502A patent/IL158905A0/xx unknown
- 2002-06-05 CZ CZ20033376A patent/CZ300052B6/cs not_active IP Right Cessation
- 2002-06-05 PL PL02366721A patent/PL366721A1/xx not_active IP Right Cessation
- 2002-06-05 CN CNB028116410A patent/CN1257908C/zh not_active Expired - Lifetime
- 2002-06-05 CA CA2450274A patent/CA2450274C/en not_active Expired - Lifetime
- 2002-06-05 WO PCT/EP2002/006185 patent/WO2002100865A1/en not_active Ceased
- 2002-06-05 NZ NZ529670A patent/NZ529670A/en unknown
- 2002-06-05 EP EP02740691A patent/EP1399450B1/en not_active Expired - Lifetime
- 2002-06-05 AU AU2002314144A patent/AU2002314144B2/en not_active Expired
- 2002-06-05 RU RU2004100310/04A patent/RU2279434C2/ru not_active IP Right Cessation
- 2002-06-05 DE DE60225689T patent/DE60225689T2/de not_active Expired - Lifetime
- 2002-06-05 ES ES02740691T patent/ES2301651T3/es not_active Expired - Lifetime
- 2002-06-05 AT AT02740691T patent/ATE389659T1/de active
- 2002-06-05 KR KR1020037016150A patent/KR100863255B1/ko not_active Expired - Fee Related
- 2002-06-05 BR BR0210222-6A patent/BR0210222A/pt not_active Application Discontinuation
- 2002-06-05 US US10/480,623 patent/US7307073B2/en not_active Expired - Lifetime
- 2002-06-05 SK SK1518-2003A patent/SK287150B6/sk not_active IP Right Cessation
- 2002-06-05 HU HU0400154A patent/HUP0400154A3/hu unknown
- 2002-06-05 HR HR20031007A patent/HRP20031007A2/xx not_active Application Discontinuation
- 2002-06-05 MX MXPA03011563A patent/MXPA03011563A/es active IP Right Grant
- 2002-06-10 PE PE2002000495A patent/PE20030097A1/es not_active Application Discontinuation
- 2002-06-10 AR ARP020102171A patent/AR036092A1/es unknown
-
2003
- 2003-11-13 IS IS7036A patent/IS2526B/is unknown
- 2003-11-17 IL IL158905A patent/IL158905A/en not_active IP Right Cessation
- 2003-12-02 ZA ZA200309382A patent/ZA200309382B/en unknown
- 2003-12-04 CO CO03107046A patent/CO5550447A2/es not_active Application Discontinuation
- 2003-12-10 NO NO20035486A patent/NO328705B1/no not_active IP Right Cessation
- 2003-12-11 EC EC2003004891A patent/ECSP034891A/es unknown
-
2007
- 2007-10-25 US US11/924,451 patent/US7504390B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR022303A1 (es) | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion | |
| AR037647A1 (es) | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| ES2164657T3 (es) | Derivados aza-biciclicos puenteados como antagonistas de la sustancia p. | |
| ES2184772T3 (es) | Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos. | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| PE20020470A1 (es) | Derivados de pirazol como inhibidores de las enzimas proteina quinasas | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| BG101806A (bg) | Индолови производни като антагонисти на 5-нт рецептори | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| UY28150A1 (es) | Agentes terapeuticos | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| CY1109808T1 (el) | Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| PE54294A1 (es) | Derivado de 5-aminoalquil-1,4-benzodiazepina | |
| AR029214A1 (es) | Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza | |
| DE602006019221D1 (de) | Von dopamin-d3-rezeptoren |